Treatment of invasive aspergillosis in cancer patients

被引：0
作者：
Auberger J. [1 ]
Russ G. [1 ]
Greil R. [1 ]
Egle A. [1 ]
机构：
[1] IIIrd Med. Dept. with Hematol., Med. Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Salzburg Private Medical University Hospital, 5020 Salzburg
来源：
memo - Magazine of European Medical Oncology | 2011年 / 4卷 / 4期
关键词：
Antifungal treatment; Aspergillus; Cancer; Fungal infections; Immunocompromised; Recommendations;
D O I：
10.1007/s12254-011-0304-1
中图分类号：
学科分类号：
摘要：
Invasive fungal infections (IFI) remain a leading cause of morbidity and mortality in immunocompromised patients. Despite major improvements, it often remains difficult to obtain accurate diagnosis in neutropenic patients. Timely initiation of antifungal treatment in this high-risk population is mandatory to improve survival. Today, clinicians have a choice among a growing armamentarium of novel antifungal agents. Agents such as "veteran" amphotericin B deoxycholate (d-AMB) have been replaced with lipid formulations, and new generation triazoles as well as novel class echinocandins finally offer opportunities to improve prognosis with less systemic toxicity. Clinical decision-making depends on several guidelines, published studies and not least on economic considerations. The current review summarises up-to-date treatment recommendations of the DGHO/AGIHO, and ECIL-3, as well as the recently published 2010 Clinical Practice Guidelines of the IDSA. © Springer-Verlag 2011.
引用
收藏
页码：266 / 272
页数：6
相关论文
共 75 条
  • [31] Costa C., Costa J.M., Desterke C., Et al., Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis, J Clin Microbiol, 40, 6, pp. 2224-2227, (2002)
  • [32] Garcia M.E., Blanco J.L., Caballero J., Et al., Anticoagulants interfere with PCR used to diagnose invasive aspergillosis, J Clin Microbiol, 40, (2002)
  • [33] Florent M., Katsahian S., Vekhoff A., Et al., Prospective Evaluation of a Polymerase Chain Reaction-ELISA Targeted to Aspergillus fumigatus and Aspergillus flavus for the Early Diagnosis of Invasive Aspergillosis in Patients with Hematological Malignancies, Infect Dis, 193, 5, pp. 741-747, (2006)
  • [34] Paterson P.J., Seaton S., McHugh T.D., Et al., Validation and clinical application of molecular methods for the identification of molds in tissue, Clin Infect Dis, 42, 1, pp. 51-56, (2006)
  • [35] Rickerts V., Mousset S., Lambrecht E., Et al., Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens, Clin Infect Dis, 44, 8, pp. 1078-1083, (2007)
  • [36] Donnelly J.P., Polymerase chain reaction for diagnosing invasive aspergillosis: Getting closer but still a ways to go, Clin Infect Dis, 42, (2006)
  • [37] White P.L., Linton C.J., Perry M.D., Et al., The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting, Clin Infect Dis, 42, 4, pp. 479-486, (2006)
  • [38] Herbrecht R., Denning D.W., Patterson T.F., Et al., Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, 347, pp. 408-415, (2002)
  • [39] Pascual A., Calandra T., Bolay S., Et al., Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin Infect Dis, 46, pp. 201-211, (2008)
  • [40] Trifilio S.M., Pennick G., Pi J., Et al., Monitoring plasma Voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients, Cancer, 109, pp. 1532-1535, (2007)
12345678